The currently approveddrugs for the treatment of Alzheimer’sdisease (AD) fail to address its interconnected pathological processes.Inhibition of butyrylcholinesterase (BChE) and p38α mitogen-activatedprotein kinase (p38α MAPK) offers an innovative dual approachto mitigate two major drivers of neurodegeneration in AD: cholinergicdeficit and neuroinflammation. This evidence concerns the gene BCHE and Alzheimer disease.